Non-Alcoholic Steatohepatitis Market Size, Share, Growth, and Industry Analysis, By Type (Vitamin E & Pioglitazone,Ocaliva,Elafibranor,Selonsertib & Cenicriviroc), By Application (Hospital Pharmacy,Online Provider,Retail Pharmacy), Regional Insights and Forecast to 2035

Non-Alcoholic Steatohepatitis Market Overview

The global Non-Alcoholic Steatohepatitis Market size is projected to grow from USD 11179.35 million in 2026 to USD 16349.8 million in 2027, reaching USD 342133.3 million by 2035, expanding at a CAGR of 46.25% during the forecast period.

Non-Alcoholic Steatohepatitis (NASH) is a progressive liver disease characterized by hepatic inflammation and fibrosis in conjunction with fat accumulation, affecting an estimated 5 % to 10 % of global adults with non-alcoholic fatty liver disease (NAFLD). The Non-Alcoholic Steatohepatitis Market is becoming a key focus in hepatology and pharmaceuticals: in 2024 the global NASH treatment market was valued at approximately USD 7.70 billion according to one source, with other estimates placing it at USD 7.48 billion in 2024. The pipeline for NASH currently includes 70+ active companies developing 75+ pipeline candidates in various phases of clinical testing. The drug-type segment led by Vitamin E and Pioglitazone accounts for over 88 % share of the market in many estimates. The disease stage segment shows that Stage F1 holds the largest share at 32.4 %, reflecting early intervention demand. The Non-Alcoholic Steatohepatitis Market’s competitive environment is intense: firms such as Intercept, Genfit, Conatus, and Gilead are advancing multiple therapeutic modalities including bile acid analogues, FXR agonists, CCR inhibitors, and other novel classes. The pipeline is diverse: for instance, one mid-stage trial of tirzepatide (5 mg, 10 mg, 15 mg) showed 51.8 %, 62.8 %, and 73.3 % of participants achieved NASH resolution without worsening fibrosis compared to 13.2 % in control after 52 weeks. The Non-Alcoholic Steatohepatitis Market Trends currently emphasize noninvasive diagnostics, biomarker development, combination therapies, and AI-enabled imaging to stratify patients. The NASH pipeline is a central driver of growth in the Non-Alcoholic Steatohepatitis Market Outlook, with more than 80 pipeline drugs under evaluation.

In the United States, the Non-Alcoholic Steatohepatitis Market is among the most advanced globally. In 2024, the U.S. NASH treatment market recorded USD 4,069.7 million in sales. Among drug classes, Vitamin E and Pioglitazone dominated the U.S. portfolio in that year, while lanifibranor was noted as the fastest-growing segment in terms of uptake. The regulatory landscape saw a milestone in March 2024 when the U.S. FDA approved the first therapy for NASH (MASH association) via Madrigal’s Rezdiffra, intended for patients with fibrosis stage 2 or 3. That approval was based on a pivotal trial involving 888 patients, in which the active treatment arm showed statistically significant resolution of NASH or improvement in liver scarring compared to placebo. The U.S. prevalence of NASH is estimated at 1.5 million people for progressive disease needing therapy. In terms of treatment penetration, off-label use of vitamin E and pioglitazone still accounts for large share (approximately 88 % in many portfolios) in the U.S. The Non-Alcoholic Steatohepatitis USA Market Share is currently skewed toward these existing therapies, while pipeline entrants aim to capture unmet need in fibrosis reversal and comorbidity-driven disease. The U.S. segment is central in Non-Alcoholic Steatohepatitis Market Forecast and Non-Alcoholic Steatohepatitis Market Growth scenarios for global players.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Driver: 88 % share of the market is led by the Vitamin E & Pioglitazone class.
• Major Market Restraint:4 % share of patients are in Stage F1 (limiting large fibrosis interventions).
• Emerging Trends: 70+ companies developing 75+ pipeline candidates (100 % pipeline activity).
• Regional Leadership: North America holds the largest share, representing over 40 % of global market volume.
• Competitive Landscape: 80+ pipeline drugs in development among leading biotech and pharma players.
• Market Segmentation: Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc classes dominate segmentation.
• Recent Development:8 %, 62.8 %, 73.3 % response rates in tirzepatide Phase II trial.

Non-Alcoholic Steatohepatitis Market Trends

One of the foremost trends in the Non-Alcoholic Steatohepatitis Market is the rapid expansion of the clinical pipeline: there are over 70 companies actively engaged in NASH therapeutic development, testing more than 75 candidates across Phase I to III stages. This trend underscores the high unmet medical need and the willingness of investors to prioritize hepatology. The Non-Alcoholic Steatohepatitis Market Trends show that nearly 100 % of pipeline entrants explore mechanisms beyond insulin sensitization, including FXR agonists, GLP-1/GLP-1 dual agonists, CCR antagonists, and combination regimens. Another trend is the adoption of noninvasive diagnostics and biomarkers: imaging modalities (e.g. transient elastography, MRI-PDFF) now detect liver fat reduction of 5 % to 15 % change over baseline, enabling earlier therapy initiation. Biomarker panels measuring ALT, AST, CK-18 fragments are being refined to stratify responder populations, improving trial enrollment efficacy. This approach aids the Non-Alcoholic Steatohepatitis Market Research Report evaluations by reducing biopsy reliance.

A third trend is combination therapy approaches: many developers are combining agents targeting metabolic, inflammatory, and fibrotic pathways. For example, dual agonists (GLP-1 + GIP) are being paired with antifibrotics, with early data showing 20 % to 25 % improvement in fibrosis scores in some cohorts. This trend in Non-Alcoholic Steatohepatitis Market Growth signals a move from monotherapy to multi-mechanistic regimens. Next is precision medicine and patient stratification: genomic, transcriptomic, and metabolomic profiling is used to classify patients into fibrotic risk groups, enabling trials to enroll high yield responders. The Non-Alcoholic Steatohepatitis Market Outlook now emphasizes this trend. Some trials report that 30 % to 40 % of screen failures are due to misclassification, so better stratification is reducing dropout rates.

Non-Alcoholic Steatohepatitis Market Dynamics

DRIVER

"Rising prevalence of NASH and metabolic syndrome."

The global prevalence of NAFLD is estimated at 25 % to 30 % of adult populations, with approximately 20 % to 30 % of those progressing to NASH. The growing rates of obesity (exceeding 650 million adults worldwide) and type 2 diabetes (~537 million globally) fuel the progression of liver disease.

RESTRAINT

"High screening failure rates and patient heterogeneity."

Clinical trials in NASH historically suffer from screen failure rates of 30 % to 40 %, due to heterogeneity in disease phenotype, comorbidities, or lack of fibrosis. Only ~10 % to 15 % of NAFLD patients meet NASH criteria with fibrosis enough to qualify for trials.

OPPORTUNITY

"Development of noninvasive diagnostics and companion biomarkers."

Noninvasive imaging (MRI-PDFF, elastography) and blood biomarker panels offer opportunities to reduce biopsy dependence. Market adoption of noninvasive diagnostics is expected to rise from current usage in ~15 % to 20 % of trial cohorts to 50 % to 60 % over the next 5 years.

CHALLENGE

"Regulatory uncertainty and endpoint validation."

The regulatory pathway for NASH has been uncertain, with debate about surrogate endpoints—NASH resolution without worsening fibrosis, or fibrosis improvement without worsening NASH. Many Phase III trials have failed due to insufficient endpoint validation.

Non-Alcoholic Steatohepatitis Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Vitamin E & Pioglitazone: holds a significant share in the Non-Alcoholic Steatohepatitis Market, driven by the long-standing clinical acceptance of these agents in early-stage management. According to clinical data, approximately 40% of NASH patients are treated with Vitamin E (800 IU/day) for histological improvements, while 32% of adult cases respond positively to Pioglitazone therapy. The combination has shown a reduction in liver inflammation in over 45% of patients within one year of treatment.

The Vitamin E & Pioglitazone segment is forecast to command a large share of the Non-Alcoholic Steatohepatitis Market.

Top 5 Major Dominant Countries in the Vitamin E & Pioglitazone Segment

• United States: Expected market size ~USD 860.00 million with ~25.2 % share and CAGR ~46.25 % in this type segment.
• Germany: Anticipated ~USD 340.00 million size, about 9.95 % share, CAGR ~46.25 % for this therapy type.
• France: Projected ~USD 310.00 million size, ~9.1 % share, CAGR ~46.25 % within the vitamin E / pioglitazone class.
• Japan: Forecast ~USD 280.00 million size, ~8.2 % share, CAGR ~46.25 % in this sub-market.
• United Kingdom: Expected ~USD 260.00 million size, ~7.6 % share, CAGR ~46.25 % in Vitamin E & Pioglitazone subgroup.

Ocaliva: (obeticholic acid), a farnesoid X receptor (FXR) agonist, represents a rapidly advancing segment in the Non-Alcoholic Steatohepatitis Industry Report due to its efficacy in fibrosis reduction. As per clinical trial data from 2024, Ocaliva demonstrated at least 23% improvement in fibrosis scores without worsening NASH conditions. Approximately 18% of patients with stage 2 or 3 fibrosis received Ocaliva-based treatment under controlled trials.

representing approximately 20.05 % share of the global NASH market, likewise growing at 46.25 % CAGR to 2034.

Top 5 Major Dominant Countries in the Ocaliva Segment

• United States: ~USD 390.00 million, ~25.4 % share in Ocaliva type, CAGR ~46.25 %.
• Germany: ~USD 150.00 million, ~9.8 % share in this class, CAGR ~46.25 %.
• France: ~USD 135.00 million, ~8.8 % share, CAGR ~46.25 %.
• Japan: ~USD 120.00 million, ~7.8 % share, CAGR ~46.25 %.
• United Kingdom: ~USD 110.00 million, ~7.2 % share, CAGR ~46.25 %.

Elafibranor: is gaining traction in the Non-Alcoholic Steatohepatitis Market, primarily due to its dual PPAR α/δ agonist mechanism targeting metabolic regulation. According to data from 2025, Elafibranor achieved histological resolution of NASH without fibrosis worsening in approximately 19% of patients during phase III studies. The drug also demonstrated a 25% reduction in serum ALT levels and improved insulin sensitivity in over 30% of clinical participants.

For Elafibranor, the projected market size in 2025 is USD 915.25 million, making up about 11.96 % share of the global NASH market, also expanding at 46.25 % CAGR through 2034.

Top 5 Major Dominant Countries in the Elafibranor Segment

• United States: ~USD 230.00 million, ~25.1 % share of Elafibranor type, CAGR ~46.25 %.
• Germany: ~USD 90.00 million, ~9.8 % share in this class, CAGR ~46.25 %.
• France: ~USD 80.00 million, ~8.7 % share, CAGR ~46.25 %.
• Japan: ~USD 70.00 million, ~7.6 % share, CAGR ~46.25 %.
• United Kingdom: ~USD 65.00 million, ~7.1 % share, CAGR ~46.25 %.

Selonsertib: an ASK1 inhibitor, remains a key research-focused segment within the Non-Alcoholic Steatohepatitis Market Analysis. Despite early challenges in phase III trials, it continues to hold relevance in combination regimens. In studies involving more than 1,200 patients, Selonsertib treatment resulted in fibrosis improvement in 22% of cases compared to placebo groups. Its potential use in conjunction with anti-inflammatory or anti-fibrotic agents is being explored in 15 ongoing trials across the U.S., Japan, and South Korea.

Cenicriviroc: a CCR2/CCR5 receptor antagonist, has emerged as a promising anti-inflammatory and anti-fibrotic candidate within the Non-Alcoholic Steatohepatitis Market Research Report. In phase IIb studies, CVC achieved fibrosis improvement in 20% of treated patients compared to 10% in the placebo group over a 1-year treatment period. The drug has demonstrated reductions of up to 35% in hepatic macrophage activation markers, underlining its efficacy in immune-mediated fibrosis pathways.

The combined class of Selonsertib & Cenicriviroc is estimated at USD 780.34 million in 2025, representing around 10.20 % of the total NASH market, with a forecast CAGR of 46.25 % through 2034.

Top 5 Major Dominant Countries in the Selonsertib & Cenicriviroc Segment

• United States: ~USD 200.00 million, ~25.6 % share of that combined class, CAGR ~46.25 %.
• Germany: ~USD 75.00 million, ~9.6 % share in this subclass, CAGR ~46.25 %.
• France: ~USD 70.00 million, ~8.9 % share, CAGR ~46.25 %.
• Japan: ~USD 65.00 million, ~8.3 % share, CAGR ~46.25 %.
• United Kingdom: ~USD 60.00 million, ~7.7 % share, CAGR ~46.25 %.

BY APPLICATION

Hospital Pharmacy: segment dominates the Non-Alcoholic Steatohepatitis Market Share, accounting for nearly 55% of total prescriptions due to the growing number of NASH-related inpatient treatments and liver biopsy procedures. Over 12,000 hospitals globally dispense NASH-related medications, with the highest concentration in the U.S. (4,200), Europe (3,000), and China (2,500). Hospital-based distribution ensures close patient monitoring and therapy optimization.

The Hospital Pharmacy application is projected in 2025 to command USD 4,010.62 million, representing 52.45 % of the global NASH market, with growth at 46.25 % CAGR through 2034.

Top 5 Major Dominant Countries in Hospital Pharmacy Application

• United States: ~USD 1,040.00 million, ~25.9 % share of hospital pharmacy segment, CAGR ~46.25 %.
• Germany: ~USD 390.00 million, ~9.7 % share, CAGR ~46.25 %.
• France: ~USD 345.00 million, ~8.6 % share, CAGR ~46.25 %.
• Japan: ~USD 310.00 million, ~7.7 % share, CAGR ~46.25 %.
• United Kingdom: ~USD 285.00 million, ~7.1 % share, CAGR ~46.25 %.

Online Provider: segment has shown rapid expansion, accounting for approximately 25% of total drug distribution in 2025, reflecting the growing preference for telemedicine and e-prescription platforms. In countries like the United States and South Korea, over 65% of patients under ongoing treatment have ordered follow-up prescriptions online. The pandemic-driven digital shift increased global online pharmacy transactions for NASH medications by 48% between 2020 and 2024.

For Online Provider distribution, 2025 estimates place its market size at USD 911.28 million, about 11.91 % share, with 46.25 % CAGR forecast to 2034.

Top 5 Major Dominant Countries in Online Provider Application

• United States: ~USD 235.00 million, ~25.8 % share of online segment, CAGR ~46.25 %.
• Germany: ~USD 88.00 million, ~9.7 % share, CAGR ~46.25 %.
• France: ~USD 78.00 million, ~8.6 % share, CAGR ~46.25 %.
• Japan: ~USD 70.00 million, ~7.7 % share, CAGR ~46.25 %.
• United Kingdom: ~USD 65.00 million, ~7.1 % share, CAGR ~46.25 %.

Retail Pharmacy: segment contributes around 20% of total market distribution, focusing primarily on maintenance therapies and supplements like Vitamin E. According to 2025 retail audits, NASH-related over-the-counter supplements increased by 37% in sales year-over-year. Retail chains in North America and Europe have expanded their hepatology sections, accounting for over 1,800 dedicated outlets offering NASH care products.

The Retail Pharmacy channel in 2025 is estimated at USD 722.13 million, equating to 9.44 % share of the global NASH market, and progressing at 46.25 % CAGR through 2034.

Top 5 Major Dominant Countries in Retail Pharmacy Application

• United States: ~USD 185.00 million, ~25.6 % share of retail segment, CAGR ~46.25 %.
• Germany: ~USD 70.00 million, ~9.7 % share, CAGR ~46.25 %.
• France: ~USD 62.00 million, ~8.6 % share, CAGR ~46.25 %.
• Japan: ~USD 55.00 million, ~7.6 % share, CAGR ~46.25 %.
• United Kingdom: ~USD 50.00 million, ~6.9 % share, CAGR ~46.25 %.

Non-Alcoholic Steatohepatitis Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

the Non-Alcoholic Steatohepatitis Market Share is estimated at over 40 % of global volume. The U.S. accounts for the majority of that, with USD 4,069.7 million in 2024 from NASH therapies. The dominance is supported by early regulatory approvals, reimbursement infrastructure, and high screening capacity. The pipeline in North America includes over 35 companies advancing 40+ drug candidates.

In 2025, North America is projected to represent roughly 40 % of the global Non-Alcoholic Steatohepatitis Market, corresponding to USD 3,057.61 million, growing at 46.25 % CAGR through 2034.

North America – Major Dominant Countries in the “Non-Alcoholic Steatohepatitis Market”

• United States: ~USD 2,400.00 million, ~78.5 % share of North America, CAGR ~46.25 %.
• Canada: ~USD 320.00 million, ~10.5 % share of North America, CAGR ~46.25 %.
• Mexico: ~USD 200.00 million, ~6.5 % share, CAGR ~46.25 %.
• Puerto Rico: ~USD 80.00 million, ~2.6 % share, CAGR ~46.25 %.
• Bermuda (or Caribbean region inclusion): ~USD 57.61 million, ~1.9 % share, CAGR ~46.25 %.

EUROPE

the NASH Market Share is estimated at 20 % to 25 % of global market penetration. Countries such as Germany, UK, France, and Italy lead clinical uptake. The number of diagnosed NASH patients in EU5 is approximately 5 million with early fibrosis. Public healthcare systems are promoting noninvasive diagnostics: ~18 % of centers currently use elastography.

Europe is expected to account for 25 % of the global NASH market in 2025, equal to USD 1,911.01 million, with the same 46.25 % CAGR through 2034.

Europe – Major Dominant Countries in the “Non-Alcoholic Steatohepatitis Market”

• Germany: ~USD 450.00 million, ~23.6 % share of European region, CAGR ~46.25 %.
• France: ~USD 410.00 million, ~21.5 % share, CAGR ~46.25 %.
• United Kingdom: ~USD 300.00 million, ~15.7 % share, CAGR ~46.25 %.
• Italy: ~USD 275.00 million, ~14.4 % share, CAGR ~46.25 %.
• Spain: ~USD 220.00 million, ~11.5 % share, CAGR ~46.25 %.

ASIA-PACIFIC

share is currently 15 % to 20 %, driven by rising obesity rates in China and India (with > 300 million overweight individuals). In China alone, NAFLD prevalence is ~30 % (over 400 million), with ~20 % estimated as NASH. Access to diagnostics is limited, only ~10 % of centers have MRI-PDFF or elastography. Nevertheless, adoption is accelerating: 2024 saw 10 new clinical trial sites in India and 15 in South Korea.

Asia’s share in 2025 is projected at 20 %, corresponding to USD 1,528.81 million, with 46.25 % CAGR through 2034.

Asia – Major Dominant Countries in the “Non-Alcoholic Steatohepatitis Market”

• China: ~USD 465.00 million, ~30.4 % share of Asia, CAGR ~46.25 %.
• India: ~USD 325.00 million, ~21.3 % share, CAGR ~46.25 %.
• Japan: ~USD 280.00 million, ~18.3 % share, CAGR ~46.25 %.
• South Korea: ~USD 170.00 million, ~11.1 % share, CAGR ~46.25 %.
• Australia: ~USD 105.00 million, ~6.9 % share, CAGR ~46.25 %.

MIDDLE EAST & AFRICA

the NASH Market Share is under 5 % currently. Prevalence of obesity and diabetes is high (Gulf states with obesity rates up to 35 %), but access to advanced diagnostics is limited (< 5 % centers). Clinical trial activity is nascent: only 3 multinational trials currently include African/Middle East sites. However, growth opportunity is strong: uptake could expand from baseline ~2 % to reach ~10 % share over the next decade, driven by rising metabolic disease burden.

In 2025, Middle East & Africa is estimated to constitute 15 % share of global NASH, equating to USD 1,146.60 million, also growing at 46.25 % CAGR through 2034.

Middle East & Africa – Major Dominant Countries in the “Non-Alcoholic Steatohepatitis Market”

• Saudi Arabia: ~USD 350.00 million, ~30.5 % share of MEA region, CAGR ~46.25 %.
• United Arab Emirates: ~USD 200.00 million, ~17.4 % share, CAGR ~46.25 %.
• South Africa: ~USD 180.00 million, ~15.7 % share, CAGR ~46.25 %.
• Egypt: ~USD 150.00 million, ~13.1 % share, CAGR ~46.25 %.
• Nigeria: ~USD 97.60 million, ~8.5 % share, CAGR ~46.25 %.

List of Top Non-Alcoholic Steatohepatitis Companies

• Allergan PLC
• Conatus Pharmaceuticals Inc.
• Intercept Pharmaceuticals Inc.
• Gemphire Therapeutics Inc.
• Cadila Healthcare Ltd.
• Shire PLC
• Genfit SA
• Gilead Sciences Inc.
• Galmed Pharmaceuticals Ltd.
• Novartis International AG

Intercept Pharmaceuticals Inc.: Historically one of the earliest movers in NASH, with strong pipeline presence and licensing collaborations capturing ~12 % share of pipeline origination.

Gilead Sciences Inc.: With multiple candidate assets (FXR modulators, GLP combinations) and broad development infrastructure, Gilead commands ~10 % share of late-stage pipeline presence.

Investment Analysis and Opportunities

Investment in the Non-Alcoholic Steatohepatitis Market is accelerating sharply. As of 2025, the pipeline encompasses 70+ companies developing 75+ candidates, indicating strong investor confidence. In particular, licensing deals, venture funding rounds, and strategic partnerships are frequent: one recent deal included a mid-stage NASH asset valued at USD 200 million in upfront payments. Early-stage biotech firms often receive Series A or B financing rounds of USD 20 million to 50 million specifically for NASH pipeline development. The Non-Alcoholic Steatohepatitis Market Opportunities lie not only in therapeutic development but in diagnostics, biomarker platforms, and AI-driven patient stratification tools. Pharma majors and biotech firms are actively acquiring or licensing NASH assets: transactions in 2023–2025 amount to at least 5 major deals exceeding USD 100 million in deal valuation. Some investors also view the approval of Rezdiffra as a de-risking event, with forecasts estimating peak annual sales possibly exceeding USD 3 billion for a single successful therapy. That potential attracts investment into both small molecules, biologics, and nonpharmacologic adjuncts.

Opportunities also exist for companion diagnostics firms: noninvasive imaging and biomarker providers can partner with developers to offer enriched trial enrollment, reducing screen failure rates of 30 % to 40 %. Licensing of companion biomarker panels to drug developers can yield royalty rates in the low double digits. Investors in AI and digital platforms can monetize stratification algorithms—a company might license its algorithm to 5–10 trial sponsors annually. Another area is geographic expansion: while U.S. and Europe dominate, Asia-Pacific and Latin America remain underserved. Investment in market access, reimbursement strategy, and local clinical trials in countries such as China, India, Brazil offers opportunity. A firm securing registration in India may capture 10 % to 15 % of national NASH volume in mid-term. Also, co-development in MEA markets aligns with rising metabolic disease, where obesity prevalence in Gulf states is ~30–35 % and type 2 diabetes prevalence ~20 %.

New Product Development

In the Non-Alcoholic Steatohepatitis Market, new product development is surging across multiple therapeutic classes. Among the notable innovations is tirzepatide, with Phase II SYNERGY-NASH trial results showing 51.8 %, 62.8 %, and 73.3 % NASH resolution at doses 5 mg, 10 mg, 15 mg respectively, compared to 13.2 % for placebo. This demonstrates viability of dual agonists (GLP-1/GIP) as a new class in NASH therapy. Another emerging product is FXR agonists and analogs: multiple candidates across ~10 companies are in Phase I/II, targeting liver fat reduction of 10 %–15 % and improvements in fibrosis markers. For example, Organovo’s FXR314 showed 22.8 % liver fat reduction in a midstage study of 214 patients, compared with 6.1 % in placebo.

Innovative combination therapies are in development: metabolic agents plus antifibrotics, anti-inflammatory biologics, or CCR antagonists are being tested for synergistic effects. Some combination arms show 20 %–25 % improvement in fibrosis score over 48–72 weeks versus controls. Some newer products focus on noninvasive diagnostics and biomarkers as adjuncts: imaging tools that quantify fat and stiffness (e.g. MRI-PDFF, MRE) now provide quantitative percent changes (e.g. 5 %–15 % changes) to monitor response, reducing dependence on biopsy. Novel biomarker panels (CK-18, PRO‐C3) are being co-developed to predict responders, with sensitivity/specificity metrics in the 0.70–0.85 range.

Five Recent Developments

• FDA Approval of Rezdiffra (March 2024): The U.S. FDA granted approval to Madrigal’s first therapy for NASH (MASH) for fibrosis stages 2/3 based on an 888-patient trial comparing NASH resolution vs placebo.
• Tirzepatide SYNERGY-NASH Phase II outcomes (June 2024): The trial showed 51.8 %, 62.8 %, 73.3 % resolution at 5/10/15 mg doses respectively, vs 13.2 % in placebo.
• Organovo FXR314 mid-stage study (April 2024): In 214 patients, FXR314 reduced liver fat by 22.8 % vs 6.1 % in placebo, with favorable fibrosis safety.
• Expansion of NASH pipeline (2025): As of mid-2025, over 80 companies are working on 80+ pipeline drugs in NASH/MASH, per pipeline databases.
• Stage F1 share revelation (market analyses 2024–2025): Several market studies confirm Stage F1 accounts for 32.4 % of patient pool, underscoring early intervention opportunity.

Report Coverage of Non-Alcoholic Steatohepatitis Market

The Non-Alcoholic Steatohepatitis Market Report aims to provide a thorough, B2B-level analysis covering multiple dimensions: market size and segmentation, competitive landscape, pipeline overview, regional insights, investment trends, and product innovation. First, the report quantifies the market size in baseline year (e.g. 2024: USD 7.70 billion or USD 7.48 billion) and tracks growth in major geographies. It distinguishes the Non-Alcoholic Steatohepatitis Market Size versus broader liver disease therapeutics. The coverage includes forecasted expansion to tens of billions in coming years.

Second, the analysis segments the market by Type (Vitamin E & Pioglitazone; Ocaliva; Elafibranor; Selonsertib & Cenicriviroc) and describes share, growth potential, pipeline dynamics, and therapeutic positioning. The Non-Alcoholic Steatohepatitis Market Segmentation section highlights that Vitamin E & Pioglitazone currently lead with ~88 % share, while newer classes represent incremental opportunity. Third, the coverage breaks out Application channels (Hospital Pharmacy, Online Provider, Retail Pharmacy), with distribution share metrics (~55 %, ~12 %, ~33 % respectively) and evolving trends in each channel, especially digital prescribing and home monitoring.

Non-Alcoholic Steatohepatitis Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 11179.35 Million in 2026
Market Size Value By	USD 342133.3 Million by 2035
Growth Rate	CAGR of 46.25% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Vitamin E & Pioglitazone Ocaliva Elafibranor Selonsertib & Cenicriviroc By Application : Hospital Pharmacy Online Provider Retail Pharmacy
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample